Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2026)

Tango Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 14.14% year-over-year to -$45.5 million in Q1 2026; TTM through Mar 2026 was -$107.2 million, a 18.93% increase from a year earlier, with the FY2025 full-year figure at -$101.6 million, up 22.03% from the prior year.
• Income towards Parent Company retreated to -$45.5 million in Q1 2026 per TNGX's latest filing, from -$38.7 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $15.9 million in Q3 2025 and bottomed at -$45.5 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$29.1 million (2022), against an average of -$28.7 million.
• Across the five-year window, Income towards Parent Company slumped 453.26% in 2022 and surged 154.46% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$29.1 million in 2022, then fell by 5.58% to -$30.7 million in 2023, then fell by 22.59% to -$37.7 million in 2024, then fell by 2.86% to -$38.7 million in 2025, then slipped by 17.46% to -$45.5 million in 2026.
• Per Business Quant, the three latest TNGX Income towards Parent Company figures stand at -$45.5 million (Q1 2026), -$38.7 million (Q4 2025), and $15.9 million (Q3 2025).